Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib: letters to the editor
Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) Editorial |
| Language: | English |
| Published: |
15 September 2015
|
| In: |
Leukemia
Year: 2015, Volume: 29, Issue: 12, Pages: 2402-2404 |
| ISSN: | 1476-5551 |
| DOI: | 10.1038/leu.2015.245 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1038/leu.2015.245 Verlag, Volltext: https://www-nature-com.ezproxy.medma.uni-heidelberg.de/articles/leu2015245 
|
| Author Notes: | K. Wenn, L. Tomala, S. Wilop, L. Vankann, C. Hasenbank, O. Frank, A. Hochhaus, F.J. Giles, T. Lange, M.C. Müller, S. Koschmieder, F. Beier, P. Ziegler, T.H. Brümmendorf |
| Summary: | Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib |
|---|---|
| Item Description: | Gesehen am 12.12.2017 |
| Physical Description: | Online Resource |
| ISSN: | 1476-5551 |
| DOI: | 10.1038/leu.2015.245 |